Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?

• 資料種別: 博士論文
• ISSN: 2005-0399
• タイトル: Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
• 巻次・部編番号: 30 5
• 著者・編者: 米岡, 完; YONEOKA, Yutaka
• 著者標目: 米岡, 完; YONEOKA, Yutaka
• 出版事項: Asian Society of Gynecologic Oncology
• 出版年月日等: 2019-09
• 出版年（W3CDTF）: 2019-09
• タイトル（掲載誌）: Journal of J Gynecologic Oncology
• 授与機関名: 滋賀医科大学
• 授与年月日: 2021-03-09
• 授与年月日（W3CDTF）: 2021-03-09
• 報告番号: 乙第455号
• 学位: 博士（医学）
• 博論授与番号: 乙第455号
• 本文の言語コード: eng
• 件名標目: CA-125 Antigen; Cytoreduction Surgical Procedures; Neoadjuvant Therapy; Ovarian Neoplasm
• 対象利用者: 一般
• 一般注記: pdf; Objective:To treat advanced ovarian cancer, interval debulking surgery (IDS) is performed after 3 cycles each of neoadjuvant chemotherapy (NAC) and postoperative chemotherapy (IDS group). If we expect that complete resection cannot be achieved by IDS, debulking surgery is performed after administering additional 3 cycles of chemotherapy without postoperative chemotherapy (Add-C group). We evaluated the survival outcomes of the Add-C group and determined their serum cancer antigen 125 (CA125) levels to predict complete surgery.; Methods:A retrospective chart review of all stage III and IV ovarian, fallopian tube, and peritoneal cancer patients treated with NAC in 2007-2016 was conducted.; Results:About 117 patients comprised the IDS group and 26 comprised the Add-C group. Univariate and multivariate analyses revealed that Add-C group had an equivalent effect on progression-free survival (PFS; p=0.09) and overall survival (OS; p=0.94) compared with the IDS group. Multivariate analysis revealed that patients who developed residual disease after surgery had worse PFS (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.45-3.28) and OS (HR=2.33; 95% CI=1.43-3.79), and those who received <6 cycles of chemotherapy had worse PFS (HR=5.30; 95% CI=2.56-10.99) and OS (HR=3.05; 95% CI=1.46-6.38). The preoperative serum CA125 cutoff level was 30 U/mL based on Youden index method.; Conclusions:Administering 3 additional cycles of chemotherapy followed by debulking surgery exhibited equivalent effects on survival as IDS followed by 3 cycles of postoperative chemotherapy. Preoperative serum CA125 levels of ≤30 U/mL may be a useful predictor of achieving complete surgery.; Thesis or Dissertation; 令和2年度; 10.3802/jgo.2019.30.e81; 博士論文要旨
• DOI: info:doi/10.3802/jgo.2019.30.e81; https://doi.org/info:doi/10.3802/jgo.2019.30.e81
• 国立国会図書館永続的識別子: info:ndljp/pid/11710937; https://dl.ndl.go.jp/pid/11710937
• コレクション（共通）: 障害者向け資料
• コレクション（障害者向け資料：レベル1）: テキストデータ
• コレクション（個別）: 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• 収集根拠: 博士論文（自動収集）
• 受理日（W3CDTF）: 2021-08-09T17:15:52+09:00
• 作成日（W3CDTF）: 2021-07-14
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: 国立国会図書館内限定公開
• デジタル化資料送信: 図書館・個人送信対象外
• 遠隔複写可否（NDL）: 可
• 関連情報（URI）: http://hdl.handle.net/10422/00013005
• 掲載誌（URI）: http://hdl.handle.net/10422/00013044; https://shiga-med.repo.nii.ac.jp/records/3946
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

目次

2023-09-08 再収集